CYTK insider trading — Cytokinetics Inc
No open-market insider purchases or sales were filed for Cytokinetics Inc (CYTK) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent CYTK insider transactions
Every Form 4 filed by Cytokinetics Inc officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Oct 12, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $62.88 | $472K | Form 4 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | M · Option exercise · 10b5-1 | Direct | 3,500 | $7.80 | $27K | Form 4 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | S · Sale · 10b5-1 | Direct | 3,500 | $61.38 | $215K | Form 4 |
| Sep 28, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Sep 28, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $65.46 | $491K | Form 4 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | M · Option exercise · 10b5-1 | Direct | 3,500 | $7.80 | $27K | Form 4 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | S · Sale · 10b5-1 | Direct | 3,500 | $68.29 | $239K | Form 4 |
| Sep 15, 2026 | Landry Robert E | Director | S · Sale · 10b5-1 | Direct | 1,000 | $72.13 | $72K | Form 4 |
| Sep 15, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Indirect | 97,926 | $69.33 | $6.79M | Form 4 |
| Sep 14, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Sep 14, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $73.44 | $551K | Form 4 |
| Sep 14, 2026 | Blum Robert I | President & CEO | G · Gift · 10b5-1 | Direct | 99,276 | — | — | Form 4 |
| Sep 14, 2026 | Blum Robert I | President & CEO | G · Gift · 10b5-1 | Indirect | 97,926 | — | — | Form 4 |
| Sep 11, 2026 | Landry Robert E | Director | S · Sale · 10b5-1 | Direct | 1,000 | $74.66 | $75K | Form 4 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | M · Option exercise · 10b5-1 | Direct | 3,500 | $7.80 | $27K | Form 4 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | S · Sale · 10b5-1 | Direct | 3,500 | $75.46 | $264K | Form 4 |
| Sep 1, 2026 | Parshall B Lynne | Director | S · Sale · 10b5-1 | Direct | 5,000 | $71.48 | $357K | Form 4 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M · Option exercise · 10b5-1 | Direct | 10,000 | $23.26 | $233K | Form 4 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 10,000 | $70.24 | $702K | Form 4 |
| Aug 31, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Aug 31, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $70.24 | $527K | Form 4 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | M · Option exercise · 10b5-1 | Direct | 3,500 | $7.80 | $27K | Form 4 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | S · Sale · 10b5-1 | Direct | 3,500 | $75.82 | $265K | Form 4 |
| Aug 10, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Aug 10, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $76.76 | $576K | Form 4 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | M · Option exercise · 10b5-1 | Direct | 14,000 | $23.26 | $326K | Form 4 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 14,000 | $79.88 | $1.12M | Form 4 |
| Jul 27, 2026 | Blum Robert I | President & CEO | M · Option exercise · 10b5-1 | Direct | 7,500 | $10.60 | $80K | Form 4 |
| Jul 27, 2026 | Blum Robert I | President & CEO | S · Sale · 10b5-1 | Direct | 7,500 | $80.87 | $607K | Form 4 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | M · Option exercise · 10b5-1 | Direct | 3,500 | $7.80 | $27K | Form 4 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | S · Sale · 10b5-1 | Direct | 3,500 | $80.59 | $282K | Form 4 |
CYTK insider trading FAQ
Are insiders buying CYTK stock?
Not on the open market. In the last 90 days, Cytokinetics Inc insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading CYTK?
No insider bought or sold on the open market in the last 90 days.
Where does CYTK insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.